Abstract:A number of studies have attempted to elucidate the association between mircoRNAs (miRNAs/miRs) and cancer-associated processes. The aim of the present study was to determine how miR-499a-5p intervenes in human osteosarcoma cell proliferation and differentiation. The cancerous tissues and adjacent non-cancerous tissues of 62 patients with osteosarcoma (OS) were collected. miRNA microarray analysis revealed that 29 miRNAs were upregulated while 26 were downregulated, among which miR-499a-5p expression was the most decreased. Western blot analysis and reverse transcription-quantitative polymerase chain reaction demonstrated that the mRNA and protein expression of miR-499a-5p was lower, while that of protein phosphatase 1D (PPM1D) was higher in OS tissues compared with expression levels in normal tissues. Furthermore, miR-499a-5p expression was markedly decreased in the metastatic tumors and in those at stage III+ IV compared with the non-metastatic tumors and those at stage I, respectively. In addition, following transfection of the human OS MG-63 cell line with an miR-499a-5p mimic, the expression of miR-499a-5p was elevated while the protein and mRNA expression of PPM1D was decreased. When combining these findings with the information obtained from the Targetscan predictive software, it was confirmed that PPM1D was targeted by miR-499a-5p. In MG-63 cells transfected with an miR-499a-5p mimic, PPM1D-associated downstream proteins phosphorylated protein kinase B (p-Akt) and phosphorylated glycogen synthase kinase 3 beta (p-GSK-3 beta) were significantly downregulated compared with the negative control (NC) group, while the expression of p-Akt and p-GSK-3 beta were significantly elevated in the tumor tissues compared with the adjacent non-tumor tissues. Simultaneously, the growth and proliferation activity of MG-63 cells were notably reduced when transfected with the miR-499a-5p mimic, compared with the NC group. Therefore, it may be concluded that miR-499a-5p suppresses OS cell proliferation and differentiation by targeting PPM1D through modulation of Akt/GSK-3 beta signaling.

TGF-β1-induced Mir-202 Mediates Drug Resistance by Inhibiting Apoptosis in Human Osteosarcoma

MicroRNA-211 inhibits tumor growth and invasion through directly targeting RUNX 2 in osteosarcoma

MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion Via Targeting IGF-1R

MiR-34a and Mir-203 Inhibit Survivin Expression to Control Cell Proliferation and Survival in Human Osteosarcoma Cells

MicroRNA-200a Induces Immunosuppression by Promoting PTEN-mediated PD-L1 Upregulation in Osteosarcoma.

Mir-203 Acts As a Tumor Suppressor Gene in Osteosarcoma by Regulating RAB22A

Mir‐200c/bmi1 Axis and Epithelial–mesenchymal Transition Contribute to Acquired Resistance to BRAF Inhibitor Treatment

Mir-149-5p Inhibits Cell Growth by Regulating TWEAK/Fn14/PI3K/AKT Pathway and Predicts Favorable Survival in Human Osteosarcoma

Exosomal miR-331-3p derived from chemoresistant osteosarcoma cells induces chemoresistance through autophagy

MicroRNA-455-3p Inhibits Osteosarcoma Progression Via HSF1 Downregulation

Mir-193B Increases the Chemosensitivity of Osteosarcoma Cells by Promoting FEN1-Mediated Autophagy

Mir-16-5p Suppresses Progression and Invasion of Osteosarcoma Via Targeting at Smad3

miR-197-3p Promotes Osteosarcoma Stemness and Chemoresistance by Inhibiting SPOPL

MicroRNA-199a-3p Is Downregulated in Human Osteosarcoma and Regulates Cell Proliferation and Migration

Mir-761 Inhibits Human Osteosarcoma Progression by Targeting CXCR1.

Mir-181D-5p-foxp1 Feedback Loop Modulates the Progression of Osteosarcoma.

MicroRNA‐22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma

Knockdown of Microrna-181A Inhibits Osteosarcoma Cells Growth and Invasion Through Triggering NLRP3-dependent Pyroptosis.

Microrna-499a-5p Inhibits Osteosarcoma Cell Proliferation And Differentiation By Targeting Protein Phosphatase 1d Through Protein Kinase B/Glycogen Synthase Kinase 3 Beta Signaling

MiR-367 Negatively Regulates Apoptosis Induced by Adriamycin in Osteosarcoma Cells by Targeting KLF4.

Tumor-Suppressing Effects of Mir-429 on Human Osteosarcoma